The Medicines and Healthcare products Regulatory Agency has issued advice regarding the use of rimonabant (Acomplia®) in patients taking antidepressants or those with major depression. This announcement follows the EMEA review of the safety of this drug.
The risk of psychiatric side effects with rimonabant has caused the MHRA to advise that it should not be prescribed to patients with major depression or those being treated with antidepressants. Evidence suggests that 1 in 10 patients who take rimonabant may develop these psychiatric side effects.
Action: Previous advice placed rimonabant as a last line treatment option. This new advice will further restrict prescribing of this drug to patients who are not taking antidepressants and who have no personal history of depression.